The APOLLOE4 (NCT04770220) phase 3 trial is assessing the safety and effectiveness of ALZ-801 in patients with early AD who have two copies of the ε4 allele on the apolipoprotein E gene (APOE4/4). The gene discussed is APOE; the disease is Alzheimer disease.